CytomX Therapeutics (CTMX) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' Income from Continuing Operations fell 34806.49% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 10258.86%. This contributed to the annual value of $31.9 million for FY2024, which is 570087.87% up from last year.
- CytomX Therapeutics' Income from Continuing Operations amounted to -$14.2 million in Q3 2025, which was down 34806.49% from -$154000.0 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Income from Continuing Operations registered a high of $23.5 million during Q1 2025, and its lowest value of -$34.8 million during Q4 2021.
- Moreover, its 5-year median value for Income from Continuing Operations was -$6.5 million (2024), whereas its average is -$9.2 million.
- Examining YoY changes over the last 5 years, CytomX Therapeutics' Income from Continuing Operations showed a top increase of 215519.71% in 2024 and a maximum decrease of 50110.4% in 2024.
- Quarter analysis of 5 years shows CytomX Therapeutics' Income from Continuing Operations stood at -$34.8 million in 2021, then skyrocketed by 74.8% to -$8.8 million in 2022, then skyrocketed by 109.54% to $837000.0 in 2023, then soared by 2155.2% to $18.9 million in 2024, then plummeted by 175.38% to -$14.2 million in 2025.
- Its Income from Continuing Operations stands at -$14.2 million for Q3 2025, versus -$154000.0 for Q2 2025 and $23.5 million for Q1 2025.